Harri Salo joins Eevia Health Plc as Chief Manufacturing Officer to strengthen top management competence and capacity

Eevia Health Plc, ("Eevia" or "The Company"), is welcoming Harri Salo as our new Chief Manufacturing Officer. Harri Salo has a 15-year strong career in operations and production management in international industrial business environments. He will start Monday, January 10th, and significantly strengthen Eevia Health's management capacity and competence for developing production organization, operation, and business processes.

Harri Salo comes from a position at 9Solutions being responsible for health care delivery projects. Previously, he was head of operations at Specim, responsible for complex industrial camera production. He has experience as a project manager from Nokia and Flextronics, including expatriate positions in South-East Asia supervising ODM outsourced manufacturing. Harri's educational background is a Master of Science in Industrial Engineering and Management from the University of Oulu (2002).

"We are delighted to welcome Harri Salo to our team. He is superbly structured, analytical, and competent and will help us develop our manufacturing operations to a world-class level and secure our ability to deliver on high volume deals. His broad understanding of business processes, combined with strong leadership competence for both people and processes, is a great addition to our top team." Stein Ulve, CEO

Harri Salo will join Eevia Health on Monday, January 10th, 2022. As our new Chief Manufacturing Officer, he will overtake the manufacturing organization, which includes two production managers, five shift leaders, and 12 operators and technicians. He will take a key position in the Top Management Team. With his background in Six Sigma Lean operations and ISO quality management assurance systems, he can support our efforts to streamline our production and delivery systems.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                       Kim Nurmi-Aro, CFO, Eevia Health Plc

Email: [email protected]                      [email protected]

Telephone: +358 400 22 5967                             +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Eevia Health Plc successfully participates at Vitafoods trade show in Geneva

Eevia Health Plc, ("Eevia" or "The Company"), is taking part in the trade show "Vitafoods" in Geneva this week (10-12 May 2022).


Eevia Health Plc receives a 3,3 MSEK/0,33 MEUR sales order for bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.


Eevia Health appoints a Shareholders' Nomination Committee

Eevia Health Plc, ("Eevia" or "The Company") has appointed a Shareholders' Nomination Committee


Eevia Health appoints new distributor

Eevia Health Plc, ("Eevia" or "The Company") has appointed Select Ingredients, San Diego, California, USA, as new distributor in the territory of the USA.


Gabriella Beni joins Eevia Health Plc as the new Chief Financial Officer

Eevia Health Plc ("Eevia" or "The Company") is welcoming Gabriella Beni as our new Chief Financial Officer. Kim Nurmi-Aro will leave the Company on March 16th and the Company wishes him the very best in his new professional endeavors close to his home in the city of Vaasa. Gabriella Beni will take over the position on March 17th.


Eevia Health lands a new sales agreement for specialty plant-based nutraceutical extract worth SEK 8 million.

Eevia Health Plc ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement. The sales agreement is with a Finnish customer to supply a specialty protein and fiber plant extract with excellent nutritional values and versatile product applications for the global nutraceutical market.


Eevia Health Plc Interim Report Quarter 4 - 2021

Significant events during the fourth quarter and full-year 2021:

  • Net sales for the year grew by over 130% compared to 2020, amounting to the total revenue of KEUR 6,671.
  • During Q4, 2021 Net sales amounted to KEUR 658 compared to KEUR 1,534 in 2020. The underlying Net Sales in Q4, 2021 was KEUR 801. The underlying revenue was higher than the reported revenue. Eevia credited one sold batch in Q4-21 that needed reprocessing. Eevia will resell the batch in Q1-22.
  • EBITDA for Q4, 2021 came in at KEUR -811 (KEUR -409).
  • Eevia added several new prospects to the pipeline during the period, and the Company has ongoing negotiations for long-term contracts.
  • The order reserve increased in Q4-21. As previously communicated, among new orders were:
  • an MSEK 3,4 / MEUR 0,34 sales order for highly concentrated bilberry extract (Feno-Myrtillus® 36 Organic).
  • New sales orders for organic pine bark extract (Fenoprolic® 70 Organic).
  • A human clinical study concluded on Feno-Chaga® Organic was completed with positive results, Scientific documentation of the efficacy of Eevia's plant extracts is a crucial factor in growing customer interest and sales of Eevia's products.
  • Eevia Health successfully completed an equity issue with proceeds of KEUR 1,903 in Q4-21.
  • Eevia made a significant drive in Q4-21 to become a leader in environmental sustainability and occupational safety. We launched several new actions to reduce emissions and strengthen our sustainability. The initiative included testing various technologies, such as reversed osmosis, nanofiltration, and ultrafiltration. The target is to minimize emissions of organic compounds to air and wastewater. Reducing emissions is the right thing for the environment and supports our brand as the most sustainable extracts producer.


Harri Salo joins Eevia Health Plc as Chief Manufacturing Officer to strengthen top management competence and capacity

Eevia Health Plc, ("Eevia" or "The Company"), is welcoming Harri Salo as our new Chief Manufacturing Officer. Harri Salo has a 15-year strong career in operations and production management in international industrial business environments. He will start Monday, January 10th, and significantly strengthen Eevia Health's management capacity and competence for developing production organization, operation, and business processes.


Eevia Health Plc receives 3,4 MSEK/0,34 MEUR sales order for bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a large sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

The sales value of this order is c.335,000 EUR and the product is Feno-Myrtillus 25 bilberry extract. The order is expected to create repeat sales of this product going forward.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted